Precision medicine in action, with Cary Claiborne
As the comedian Mitch Hedberg once said, “Alcoholism is a disease, but it's the only disease you can get yelled at for having.” The stigma associated with alcohol use disorder (AUD) makes it difficult to treat it in an effective, evidence-based way.
Cary Claiborne, CEO of Adial Pharmaceuticals, believes his company’s bet on a precision treatment for AUD, for patients with a specific genetic biomarker, will help doctors and patients treat the condition like the disease it is.
The company intends to offer its ultra-low dose serotonin blocker to patients dealing with alcohol addiction who take a genetic test that indicates they’re a candidate. It’s a great example of the promise of precision medicine in action.
Check out the full interview with Claiborne and pharmaphorum editor-in-chief Jonah Comstock to learn more about Adial’s story, the challenges, and advantages of being laser-focused on a single drug candidate, and Claiborne’s thoughts on the mood at JPM 2026.
